Viridian Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92790C1045

Introduction

This page provides a comprehensive analysis of the known insider trading history of Lara Meisner. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders
Companies with Reported Insider Positions

The SEC filings indicate Lara Meisner has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
Chief Legal Officer 0
US:VRDN / Viridian Therapeutics, Inc. Chief Legal Officer 29,971
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Lara Meisner. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases VRDN / Viridian Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in VRDN / Viridian Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Max		 Price at
Max		 Max
Profit ($)		 Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRDN / Viridian Therapeutics, Inc. Insider Trades
Insider Sales VRDN / Viridian Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in VRDN / Viridian Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares		 Reported
Price		 Adjusted
Shares		 Adjusted
Price		 Cost Basis Days to
Min		 Price at
Min		 Max Loss
Avoided ($)		 Max Loss
Avoided (%)
2023-06-16 VRDN Meisner Lara 27 28.3500 27 28.3500 765 129 11.1200 -465 -60.75
2023-06-06 VRDN Meisner Lara 5,126 25.0200 5,126 25.0200 128,253
2023-06-05 VRDN Meisner Lara 499 25.0300 499 25.0300 12,490

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

VRDN / Viridian Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Lara Meisner as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change		 Share
Price		 Tran
Value		 Remaining
Value
2025-06-18 2025-06-16 4 BCAX Bicara Therapeutics Inc.
Common Stock 		S - Sale X -15,829 0 -100.00 10.43 -165,096
2025-06-18 2025-06-16 4 BCAX Bicara Therapeutics Inc.
Common Stock 		M - Exercise X 15,829 15,829 5.45 86,268 86,268
2025-03-18 2025-03-14 4 BCAX Bicara Therapeutics Inc.
Common Stock 		S - Sale X -30,620 0 -100.00 13.24 -405,513
2025-03-18 2025-03-14 4 BCAX Bicara Therapeutics Inc.
Common Stock 		S - Sale X -48,526 30,620 -61.31 12.69 -615,698 388,507
2025-03-18 2025-03-14 4 BCAX Bicara Therapeutics Inc.
Common Stock 		M - Exercise X 79,146 79,145 -7,914,600.00 5.45 431,346 431,340
2023-06-20 2023-06-16 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale -27 29,971 -0.09 28.35 -765 849,678
2023-06-20 2023-06-16 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 27 29,998 0.09 23.03 622 690,854
2023-06-20 2023-06-15 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -2,269 29,971 -7.04 28.02 -63,577 839,787
2023-06-20 2023-06-15 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 2,269 32,240 7.57 23.03 52,255 742,487
2023-06-06 2023-06-06 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale -5,126 29,971 -14.61 25.02 -128,253 749,874
2023-06-06 2023-06-06 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 5,126 35,097 17.10 18.51 94,882 649,645
2023-06-06 2023-06-05 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale -499 29,971 -1.64 25.03 -12,490 750,174
2023-06-06 2023-06-05 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 499 30,470 1.66 18.51 9,236 564,000
2023-06-06 2023-06-02 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -1,875 29,971 -5.89 24.21 -45,394 725,598
2023-06-06 2023-06-02 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 1,875 31,846 6.26 14.00 26,250 445,844
2023-03-10 2023-03-09 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -29,971 0 -100.00 29.07 -871,257
2023-01-25 2023-01-23 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -6,843 0 -100.00 35.66 -244,021
2023-01-25 2023-01-23 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 1,872 6,843 37.66 14.00 26,208 95,802
2023-01-25 2023-01-23 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 4,971 4,971 23.03 114,482 114,482
2022-12-22 2022-12-21 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -16,326 0 -100.00 29.19 -476,556
2022-12-22 2022-12-21 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 16,326 16,326 23.03 375,988 375,988
2022-12-22 2022-12-20 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -600 0 -100.00 28.07 -16,842
2022-12-22 2022-12-20 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 600 600 23.03 13,818 13,818
2022-12-19 2022-12-16 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -1,297 0 -100.00 28.44 -36,887
2022-12-19 2022-12-16 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 1,297 1,297 23.03 29,870 29,870
2022-12-19 2022-12-15 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -300 0 -100.00 28.08 -8,424
2022-12-19 2022-12-15 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 300 300 23.03 6,909 6,909
2022-12-14 2022-12-14 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -15,656 0 -100.00 28.12 -440,247
2022-12-14 2022-12-14 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 15,656 15,656 23.03 360,558 360,558
2022-12-14 2022-12-12 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -600 0 -100.00 28.05 -16,830
2022-12-14 2022-12-12 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 600 600 23.03 13,818 13,818
2022-11-16 2022-11-15 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		S - Sale X -8,125 0 -100.00 22.05 -179,156
2022-11-16 2022-11-15 4 VRDN Viridian Therapeutics, Inc.\DE
Common Stock 		M - Exercise 8,125 8,125 14.00 113,750 113,750
2022-02-03 2022-02-02 4 VRDN Viridian Therapeutics, Inc.\DE
Stock Option (Right to Buy) 		A - Award 90,000 90,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)